Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.
Report: Monoclonal antibodies for dementia lack clear benefits, show risks
By
Kristen Fischer
Jan 23, 2024
Even though amyloid-reducing monoclonal antibodies (MABs) are on the market and some research shows they may treat Alzheimer’s disease and dementia, a new research review found there aren’t clear benefits...
Hurricanes hastened the deaths of adults with dementia, study finds
By
Alicia Lasek
Mar 08, 2023
People with Alzheimer’s and related dementias (ADRD) had higher mortality rates in U.S. counties that had recently experienced a hurricane disaster, investigators report.
Brooks-LaSure: Medicare poised to re-evaluate coverage of new Alzheimer’s drugs
By
Alicia Lasek
Dec 12, 2022
In a Milken Institute summit session, the CMS administrator said that Medicare’s door is open to evaluating new data on emerging Alzheimer’s drug candidates.
Researchers receive $47M grant to study Alzheimer’s disease
By
John Roszkowski
Sep 26, 2022
Researchers from the University of California, Irvine have been awarded a $47 million grant from the National Institute on Aging to develop animal models to study the biology behind Alzheimer’s disease.
Study: Having two copies of gene mutation linked to Alzheimer’s may cause onset
By
Kristen Fischer
May 07, 2024
A new study finds that possessing two copies of a specific gene mutation that’s common in Alzheimer’s disease may be the cause behind the disease in those people.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
Not all older adults can get monoclonal antibodies for Alzheimer’s disease, study finds
By
Kristen Fischer
Sep 22, 2023
Even though newer monoclonal antibodies are available for Alzheimer’s disease, there are limits on the number of older adults who can receive them, a recent study published in Neurology finds.
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...